Clinical Trial Update: Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial of autologous dendritic cell immunotherapy plus standard treatment for advanced/metastatic renal cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• AGS-003 (RNA-loaded autologous dendritic cell vaccine)

Snippet

Sponsor: Argos Therapeutics | Conditions: Advanced Renal Cell Carcinoma, Renal Cell Carcinoma | Phase 3 | Status: TERMINATED